Previous 10 | Next 10 |
home / stock / lly / lly articles
Eli Lilly And Co’s (NYSE:LLY) CEO, David Ricks, shared the pharmaceutical giant’s plans to introduce its obesity drug, tirzepatide...
During Tuesday’s CNBC Investing Club Morning Meeting, U.S. stocks exhibited mixed performance, prompting a closer look at prevailing market t...
Higher long-term rates typically matter a lot to equity valuations. However, according to DataTrek, today’s mega-cap stocks are likely to wea...
Amgen Inc (NASDAQ:AMGN) is expected to unveil updates on various programs this year, targeting significant markets. Despite concern...
The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials ...
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct compreh...
This week, Berkshire Hathaway (NYSE: BRK-A) achieved a historic milestone as its Class A shares closed above $600,000 for the first time. The surge...
Pharmaceutical giant Eli Lilly And Co (NYSE:LLY) is set to launch its highly-anticipated obesity drug, Mounjaro (tirzepatide), in Britain...
A growing number of U.S. adolescents, facing record rates of pediatric obesity, are reportedly turning to Novo Nordisk A/S’s (NYSE:...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...